Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: Evidence from Uzbekistan

European Journal of Contraception and Reproductive Health Care

Volumn 18, Issue 2, 2013, Pages 104-111

  Raghavan, Sheila ^a   Tsereteli, Tamar ^b   Kamilov, Asamidin ^c   Kurbanbekova, Dilfuza ^d   Yusupov, Dilmurod ^d   Kasimova, Feruza ^e   Jymagylova, Dilbar ^f   Winikoff, Beverly ^a  

^a GYNUITY HEALTH PROJECTS   (United States)

^b Gynuity Health Projects   (Georgia)

^c Ministry of Health   (Uzbekistan)

^d Women's Wellness Center   (Uzbekistan)

^e TASHKENT MEDICAL ACADEMY   (Uzbekistan)

^f NONE   (Uzbekistan)

Author keywords

Medical abortion; Mifepristone; Misoprostol; Uzbekistan

Indexed keywords

MIFEPRISTONE; MISOPROSTOL; PENCROFTON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; CHILL; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; MEDICAL ABORTION; MENSTRUAL CYCLE; MUSCLE CRAMP; NAUSEA; PAIN; PREGNANCY; PRIORITY JOURNAL; UZBEKISTAN; VOMITING;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, SUBLINGUAL; ADULT; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; PREGNANT WOMEN; PROSPECTIVE STUDIES; SELF ADMINISTRATION; UZBEKISTAN; YOUNG ADULT;

EID: 84875204646     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.763225     Document Type: Article

References (33)

1. United States Census Bureau (BUCEN), International Programs Center. International Data Base. Midyear Population by Special Age Groups and Sex-Custom Region-Uzbekistan. Accessed 12 October 2012 from: http://www.census.gov/ population/international/data/idb/reg ion.php?N-%20Results%20 & T-5 & A-separate & RT-0 & Y-2012 & R-1 & C-UZ
2. International Consortium for Medical Abortion. Countries abortion profi le: Uzbekistan. Accessed 27 August 2012 from: http://www. medicalabortionconsortium. org/country/UZ/
3. Analytical and Information Centre, Ministry of Health of the Republic of Uzbekistan [Uzbekistan], State Department of Statistics, Ministry of Macroeconomics. and Statistics [Uzbekistan], and ORC Macro. 2004. Uzbekistan Health Examination Survey 2002. Calverton, Maryland, USA: Analytical and Information Centre, State Department of Statistics, and ORC Macro. Accessed 27 August 2012 from: http://measuredhs. com/pubs/pdf/FR143/00FrontMatter.pdf
4. World Health Organization. Safe abortion: Technical and policy guidance for health systems, 2nd edn. Geneva: World Health Organization 2012.
5. Royal College of Obstetricians and Gynaecologists. The care of women requesting induced abortion: Evidencebased clinical guideline number 7. London: RCOG Press 2011.
6. Faundes A. The combination of mifepristone and misoprostol for the termination of pregnancy. Int JGynaecol Obstet 2011; 115: 1-4.
7. Akin A, Dabash R, Dilbaz B, et al. Increasing women' schoices in medical abortion: Astudy of misoprostol 400g swallowed immediately or held sublingually following 200 mg mifepristone. Eur JContracept Reprod Health Care 2009; 14: 169-75.
8. Ho PC. Women' sperceptions on medical abortion. Contraception 2006; 74: 11-5.
9. Shannon C, Wiebe E, Jacot F, et al. Regimens of misoprostol with mifepristone for early medical abortion: Arandomised trial. BJOG 2006; 113: 621-8.
10. Tang OS, Xu J, Cheng L, et al. Pilot study on the use of sublingual misoprostol with mifepristone in termination of fi rst trimester pregnancy up to 9 weeks gestation. Hum Reprod 2002; 17: 1738-40.
11. Aubeny E, Chatellier G. Arandomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur JContracept Reprod Health Care 2000; 5: 171-6.
12. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002; 66: 247-50.
13. Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: Arandomized controlled trial. Obstet Gynecol 2008; 112: 1303-10.
14. Schaff EA, Dicenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception 2005; 71: 22-5.
15. Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early fi rst-trimester medical abortion. Contraception 2006; 74: 26-30.
16. Tran N, Jang M, Yong S. Feasibility, effi cacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People' sRepublic of Korea. Int JGynaecol Obstet 2010; 109: 209-12.
17. Tang OS, Chan CCW, Ng EHY, et al. Aprospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 2003; 18: 2315-8.
18. Hamoda H, Ashok PW, Dow J, et al. Apilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contraception 2003; 68: 335-8.
19. Hamoda H, Ashok PW, Flett GMM, Templeton A. Arandomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation . BJOG 2005; 112: 1102-8.
20. von Hertzen H, Huong NT, Piaggio G, et al., for the WHO Research Group on Postovulatory Methods of Fertility Regulation. Misoprostol dose and route after mifepristone for early medical abortion: Arandomised controlled noninferiority trial. BJOG 2010; 117: 1186-96.
21. Raghavan S, Comendant R, Digol I, et al. Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: Arandomized controlled trial of sublingual and oral misoprostol. Contraception 2009; 79: 84-90.
22. Raghavan S, Comendant R, Digol I, et al. Comparison of 400 mcg buccal and 400 mcg sublingual misoprostol after mifepristone medical abortion through 63 days' LMP: Arandomized controlled trial. Contraception 2010; 82: 513-9.
23. Mundle S, Elul B, Anand A, et al. Increasing access to safe abortion services in rural India: Experiences with medical abortion in aprimary health center. Contraception 2007; 76: 66-70.
24. Dahiya K, Mann S, Nanda S. Randomized trial of oral versus sublingual misoprostol 24 hafter mifepristone for medical abortion. Arch Gynecol Obstet 2011; 284: 59-63.
25. Raymond EG, Shannon C, Weaver MA, Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: Asystematic review. Contraception 2013; 87: 26-37.
26. Bracken H, Gliozheni O, Kati K, et al. Mifepristone medical abortion in Albania: Results from apilot clinical research study. Eur JContracept Reprod Health Care 2006; 11: 38-46.
27. Akin A, Blum J, Ozalp S, et al. Results and lessons learned from asmall medical abortion clinical study in Turkey. Contraception 2004; 70: 401-6.
28. Hajri S, Blum J, Gueddana N, et al. Expanding medical abortion in Tunisia: Women' sexperiences from amulti-site expansion study. Contraception 2004; 70: 487-91.
29. Ngoc NTN, Nhan VQ, Blum J, et al. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from amultisite study in Vietnam. BJOG 2004; 111: 814-9.
30. Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in ageneral practice in Cura ç ao. Eur JContracept Reprod Health Care 2011; 16: 61-6.
31. Ministry of Health of the Republic of Moldova. Order No. 647 (21 September 2010).
32. Ministry of Health of the Republic of Moldova. Order No. 482 (14 June 2011).
33. Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol 2012; 120: 1070-6.